About Sera Prognostics
Sera Prognostics is a publicly listed company based in Salt Lake City (United States) founded in 2008. Sera Prognostics is focused on womens health diagnostics. It operates on a HealthTech model. The company has 123 employees. Sera Prognostics offers products and services including PreTRM Test and LikeMine Platform. Its focus areas include Diagnostics and Prenatal Testing. Its competitors include Mirvie and NX Prenatal; 2 of its 2 listed competitors have raised funding.
Company details
Sera Prognostics is dedicated to advancing womens health diagnostics with a focus on prenatal care. Solutions are developed to predict risks such as preterm delivery for pregnant women. The company serves healthcare providers, payers, employers, and mothers through innovative tools like the PreTRM Test and LikeMine platform. Research and innovation in maternal biomarkers are emphasized to improve neonatal outcomes and reduce healthcare costs. The healthcare sector, specifically prenatal testing, is the primary area of operation.
- Headquarters Salt Lake City, United States
- Employees 123
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website seraprognostics.com
- Social LinkedIn Facebook Instagram
- Legal Name Sera Prognostics
- Annual Revenue$268 K (USD)as on Dec 31, 2022
- Employee Count123
Products & Services of Sera Prognostics
Sera Prognostics offers a comprehensive portfolio of products and services, including PreTRM Test and LikeMine Platform.
Risk of preterm delivery is predicted through blood test.
Pregnancy outcomes are compared using extensive U.S. data.
People of Sera Prognostics
35 people are tracked at Sera Prognostics (22 in leadership, 13 in team); the tracked headcount is 123.
| Name | Role | Group |
|---|---|---|
Tiffany Inglis | Chief Medical Officer | Leadership |
Kyle Wray | Marketing Director | Leadership |
Jay Boniface | Chief Scientific Officer | Leadership |
Robert G. Harrison | Chief Information Officer | Leadership |
Debbie Jefferson | Head Of Revenue Cycle And Customer Operations | Leadership |
Patricia Brody | Director of Payer Marketing | Leadership |
Austin Aerts | Chief Financial Officer | Leadership |
Evguenia Lindgardt | Interim President & CEO | Leadership |
Thomas J Garite | VP of Clinical Sciences | Leadership |
Douglas Fisher | Chief Business Officer | Leadership |
Matthew R. | Director of IT | Leadership |
Tracey C. Fleischer, Ph.D. | Senior Director of Discovery Sciences | Leadership |
Doug Roach | Vice President Of Commercialization | Leadership |
Eric Gourley, MS, PMP, CSM | Senior Director of Project Management | Leadership |
Michael R. Foley | Chief Medical Officer | Leadership |
Paul Kearney | Chief Data Officer | Leadership |
Charles Cox | Senior Director Of Data Science | Leadership |
Sharon R. | Director of Clinical Operations | Leadership |
Robert Severinsen | Director of Laboratory Operations | Leadership |
Salil Bhowmik, PhD, CC(NRCC) | Laboratory Director | Leadership |
15 more people are available in the full profile.
Complete people profiles for Sera Prognostics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Sera Prognostics
Sera Prognostics is a publicly listed company on the NASDAQ with ticker symbol SERA in USA, operating in the Health services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date15 Jul 2021
- Listed onNASDAQ: SERA
- Listed entitySera Prognostics, Inc.
- Exchange sectorHealth services
Competitors of Sera Prognostics
Sera Prognostics has 2 listed competitors in our database, 2 of them funded. They include Mirvie and NX Prenatal.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| mirvie.com | 2019 | San Francisco, United States | $113.7M | 35 | Non-invasive blood tests for prenatal fetal health predictions are offered. | |
| nxprenatal.com | 2010 | Louisville, United States | $5.76M | Early warning blood tests for pregnancy complications are provided. |
Detailed competitors of Sera Prognostics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Diagnostics Laboratories
2 companies that operate in the same segment as Sera Prognostics (Diagnostics Laboratories) in United States, ranked by their profile score on The Company Check.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Sera Prognostics
Complete news archive for Sera Prognostics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Sera Prognostics
Sera Prognostics was founded in 2008.
Sera Prognostics is headquartered in Salt Lake City, United States. It is registered at Salt Lake City, Utah, United States.
Sera Prognostics has 123 employees.
Annual revenue of Sera Prognostics is $268K as on Dec 31, 2022.
Sera Prognostics is dedicated to advancing womens health diagnostics with a focus on prenatal care. Solutions are developed to predict risks such as preterm delivery for pregnant women. The company serves healthcare providers, payers, employers, and mothers through innovative tools like the PreTRM Test and LikeMine platform. Research and innovation in maternal biomarkers are emphasized to improve neonatal outcomes and reduce healthcare costs. The healthcare sector, specifically prenatal testing, is the primary area of operation.
Sera Prognostics's top competitors include Mirvie and NX Prenatal.
Sera Prognostics offers PreTRM Test and LikeMine Platform.
Yes, Sera Prognostics is publicly traded on NASDAQ under the ticker symbol SERA.
Sera Prognostics operates through Sera Prognostics.